Artelo Biosciences (ARTL) Research & Development (2017 - 2025)
Artelo Biosciences (ARTL) posted quarterly Research & Development of $893000.0 for Q4 2025, down 63.93% year-over-year from $2.5 million in Q4 2024, and down 29.96% quarter-over-quarter from $1.3 million in Q3 2025.
Artelo Biosciences (ARTL) Research & Development (2017 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Research & Development for 9 consecutive years, with $893000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development fell 63.93% year-over-year to $893000.0; the TTM figure through Dec 2025 stood at $5.4 million (down 9.51% YoY), while the FY2025 annual figure was $5.4 million, down 9.51% from the prior year.
- Research & Development slipped to $893000.0 in Q4 2025 per ARTL's latest filing, from $1.3 million in the prior quarter.
- Across five years, Research & Development topped out at $2.5 million in Q4 2024 and bottomed at $325000.0 in Q3 2024.
- Historically, Research & Development has averaged $1.3 million across 5 years, with a median of $1.3 million in 2021.
- Annual changes were most pronounced in 2024 — Research & Development slumped 79.5% — and 2025, when it soared 292.31%.
- Artelo Biosciences' Research & Development stood at $1.3 million in 2021, then surged by 35.59% to $1.7 million in 2022, then advanced by 23.06% to $2.1 million in 2023, then advanced by 16.57% to $2.5 million in 2024, then sank by 63.93% to $893000.0 in 2025.
- Business Quant data shows ARTL's Research & Development at $893000.0 in Q4 2025, $1.3 million in Q3 2025, and $1.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Artelo Biosciences | 111,698.23 | -488,301.77 | - | 893,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 893,000.00 |
| Sep 30, 2025 | 1.28 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | 2.48 Mn |
| Sep 30, 2024 | 325,000.00 |
| Jun 30, 2024 | 1.69 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 1.59 Mn |
| Jun 30, 2023 | 752,000.00 |
| Mar 31, 2023 | 1.24 Mn |
| Dec 31, 2022 | 1.73 Mn |
| Sep 30, 2022 | 1.08 Mn |
| Jun 30, 2022 | 1.06 Mn |
| Mar 31, 2022 | 464,000.00 |
| Nov 30, 2021 | 1.27 Mn |
| Aug 31, 2021 | 1.19 Mn |
| May 31, 2021 | 951,204.00 |
| Feb 28, 2021 | 663,359.00 |